Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaFRA:944 +4.53%51 Gross Margin % is 55.95% as of Mar. 2026, which is 31% above its 10-year median of 42.65. GuruFocus rates FRA:944 with a GF Score™ of 51/100 and a GF Value™ of €2.99. The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Biomaxima ranks worse than 53.61% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Biomaxima's Gross Profit for the
three
months ended in Mar. 2026 was €1.81 Mil. Biomaxima's Revenue for the
three
months ended in Mar. 2026 was €3.23 Mil. Therefore, Biomaxima's Gross Margin % for the quarter that ended in Mar. 2026 was 55.95%.
The historical rank and industry rank for Biomaxima's Gross Margin % or its related term are showing as below:
FRA:944'
s Gross Margin % Range Over the Past 10 Years
Min: 36.66 Med: 42.65 Max: 46.9
Current: 46.9
During the past 13 years, the highestGross Margin % of Biomaxima was 46.90%. The lowest was 36.66%. And the median was 42.65%.
FRA:944's Gross Margin % is ranked worse than 53.61% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs FRA:944: 46.90
Biomaxima had a gross margin of 55.95% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Biomaxima was 4.40% per year.
Biomaxima (FRA:944) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biomaxima had a gross margin of 55.95% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biomaxima Gross Margin % Related Terms
Biomaxima Gross Margin % Historical Data
* Premium members only.
The historical data trend for Biomaxima's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:944 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Biomaxima's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Biomaxima's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biomaxima (FRA:944) has a Gross Margin % of 55.95% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Biomaxima and its competitors. This is 31% above median its historical median of 42.65. Over the past decade, Biomaxima's Gross Margin % has ranged from 36.66 to 46.90. According to the industry distribution chart, Biomaxima ranks #104 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 53.6%.
Is Biomaxima's Gross Margin % too high?
Biomaxima's current Gross Margin % of 55.95% is 31% above median its 10-year median of 42.65. Over the past 10 years, this metric has ranged from a low of 36.66 to a high of 46.90. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Biomaxima's value of 55.95% is 9.4% above this industry median. Based on the distribution chart, Biomaxima ranks #104 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biomaxima has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #104 out of 194 companies for Gross Margin %. This places Biomaxima in the lower half of its industry. The industry median Gross Margin % is 51.14. Biomaxima's value of 55.95% is 9.4% above this benchmark. Historically, Biomaxima's own Gross Margin % has ranged from 36.66 to 46.90 over the past decade. While the company's 10-year median is 42.65 vs. the industry median of 51.14, Biomaxima has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomaxima's current Gross Margin % of 55.95% is 9.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Biomaxima and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomaxima's current Gross Margin % is 55.95%, which is 31% above median its own 10-year median of 42.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current Gross Margin % of 55.95%. The stock's GF Value™ is €2.99, compared to a current price of €1.89 — trading 36.7% below its estimated fair value. The current Gross Margin % is 55.95%, which is 31% above median its 10-year median of 42.65 and 9.4% above the Medical Diagnostics & Research industry median of 51.14. Biomaxima's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Biomaxima (FRA:944), the current Gross Margin % is 55.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (FRA:944) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of €1.89 is trading 36.7% below its estimated GF Value™ of €2.99.
Key valuation signals for FRA:944:
Gross Margin %: 55.95% (31% above median its 10-year median of 42.65)
GF Value™: €2.99 vs. price of €1.89 (36.7% below fair value)
Industry Position: 9.4% above the Medical Diagnostics & Research median (#104 of 194)
No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
51GF Score
Get the complete analysis for FRA:944
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:944 has been successfully added to your 
